Scholarlink

<p>Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent a significant advancement in the targeted therapy of lung adenocarcinoma (LUAD), markedly prolonging patient overall survival. However, resistance remains a major barrier to sustained clinical benefit. Beyond the classical EGFR resistance pathways, EGFR-independent bypass mechanisms have emerged as a critical research focus. Quiescent sulfhydryl oxidase 2 (QSOX2), linked to poor outcomes in various cancers, remains poorly studied in LUAD, with its role in tumor progression mechanisms largely unknown. In this study, we demonstrated that the specific high expression of QSOX2 in LUAD induced osimertinib resistance (OR). Mechanistically, QSOX2 directly binds to and stabilizes the transcription factor JUNB via a non-enzymatic interaction, promoting JUNB phosphorylation and nuclear translocation through AKT pathway activation. This results in the transcriptional activation of ITGB4, which in turn initiates FAK/AKT signaling to establish a positive feedback loop that ultimately drives osimertinib bypass resistance. In conclusion, this study innovatively identified the non-enzymatic function of QSOX2 in regulating OR in EGFR-mutant LUAD through the JUNB-ITGB4-FAK/AKT pathway. The QSOX2/JUNB-ITGB4 signaling axis represents a potential therapeutic target for overcoming OR and offers a novel strategy to improve outcomes in LUAD patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-enzymatic function of QSOX2 directly regulates the JUNB-ITGB4 axis and enhanced resistance to osimertinib in EGFR-mutation lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Chaoxing Liu,
  • Siya Wang,
  • Rong Qi,
  • Weiguo Gu,
  • Chen Fang,
  • Guohua Zhang,
  • Jinyu Gan,
  • Feng Yu,
  • Ke Fang,
  • Jianxiong Deng,
  • Chao Shi,
  • Feng Qiu

摘要

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent a significant advancement in the targeted therapy of lung adenocarcinoma (LUAD), markedly prolonging patient overall survival. However, resistance remains a major barrier to sustained clinical benefit. Beyond the classical EGFR resistance pathways, EGFR-independent bypass mechanisms have emerged as a critical research focus. Quiescent sulfhydryl oxidase 2 (QSOX2), linked to poor outcomes in various cancers, remains poorly studied in LUAD, with its role in tumor progression mechanisms largely unknown. In this study, we demonstrated that the specific high expression of QSOX2 in LUAD induced osimertinib resistance (OR). Mechanistically, QSOX2 directly binds to and stabilizes the transcription factor JUNB via a non-enzymatic interaction, promoting JUNB phosphorylation and nuclear translocation through AKT pathway activation. This results in the transcriptional activation of ITGB4, which in turn initiates FAK/AKT signaling to establish a positive feedback loop that ultimately drives osimertinib bypass resistance. In conclusion, this study innovatively identified the non-enzymatic function of QSOX2 in regulating OR in EGFR-mutant LUAD through the JUNB-ITGB4-FAK/AKT pathway. The QSOX2/JUNB-ITGB4 signaling axis represents a potential therapeutic target for overcoming OR and offers a novel strategy to improve outcomes in LUAD patients.